Wall Street analysts expect Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings of ($0.18) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Progenics Pharmaceuticals’ earnings, with estimates ranging from ($0.19) to ($0.17). Progenics Pharmaceuticals reported earnings per share of ($0.22) in the same quarter last year, which suggests a positive year over year growth rate of 18.2%. The company is expected to announce its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Progenics Pharmaceuticals will report full year earnings of ($0.67) per share for the current fiscal year, with EPS estimates ranging from ($0.75) to ($0.59). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.25) per share, with EPS estimates ranging from ($0.29) to ($0.21). Zacks’ EPS averages are an average based on a survey of research analysts that cover Progenics Pharmaceuticals.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Progenics Pharmaceuticals had a negative net margin of 341.41% and a negative return on equity of 94.45%. The firm had revenue of $3.88 million during the quarter, compared to analyst estimates of $3.30 million.

PGNX has been the subject of several analyst reports. Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. BidaskClub downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, September 5th. Jefferies Financial Group reissued a “buy” rating and issued a $13.00 target price on shares of Progenics Pharmaceuticals in a research note on Wednesday, August 1st. Needham & Company LLC reissued a “strong-buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a research note on Wednesday, August 1st. Finally, ValuEngine raised shares of Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Progenics Pharmaceuticals has a consensus rating of “Buy” and an average target price of $11.69.

A number of hedge funds have recently made changes to their positions in PGNX. BlackRock Inc. raised its stake in Progenics Pharmaceuticals by 14.0% in the 2nd quarter. BlackRock Inc. now owns 11,391,237 shares of the biotechnology company’s stock valued at $91,584,000 after purchasing an additional 1,401,564 shares during the last quarter. Summit Trail Advisors LLC increased its stake in shares of Progenics Pharmaceuticals by 529.5% during the 1st quarter. Summit Trail Advisors LLC now owns 408,376 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 343,505 shares during the last quarter. Carillon Tower Advisers Inc. increased its stake in shares of Progenics Pharmaceuticals by 7.8% during the 1st quarter. Carillon Tower Advisers Inc. now owns 3,948,024 shares of the biotechnology company’s stock valued at $28,070,000 after acquiring an additional 285,906 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Progenics Pharmaceuticals by 268.7% during the 1st quarter. JPMorgan Chase & Co. now owns 326,562 shares of the biotechnology company’s stock valued at $2,436,000 after acquiring an additional 237,992 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of Progenics Pharmaceuticals by 4,046.3% during the 1st quarter. UBS Group AG now owns 118,044 shares of the biotechnology company’s stock valued at $880,000 after acquiring an additional 115,197 shares during the last quarter. 88.74% of the stock is owned by hedge funds and other institutional investors.

Shares of PGNX stock opened at $6.45 on Friday. Progenics Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $9.42. The stock has a market capitalization of $483.05 million, a P/E ratio of -7.17 and a beta of 2.40. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.34 and a quick ratio of 6.34.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Featured Article: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Progenics Pharmaceuticals (PGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.